BAM
AUPH icon

Blueshift Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Blueshift Asset Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,162
Closed -$84K – 352
2022
Q3 		$84K Buy
+11,162
New +$96.6K 0.02% 561
2022
Q2 		– Sell
-25,962
Closed -$321K – 678
2022
Q1 		$321K Buy
+25,962
New +$401K 0.03% 585
2020
Q4 		– Sell
-10,043
Closed -$148K – 682
2020
Q3 		$148K Buy
+10,043
New +$145K 0.02% 561

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Blueshift Asset Management's AUPH Position: Q4 2022 in Review

Blueshift Asset Management sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2022, closing a stake of 11,162 shares — an estimated $84K sold.

Blueshift Asset Management first reported a position in AUPH in Q3 2020 and held it in 3 quarters. The position peaked at $321K in Q1 2022. 192 funds tracked by Wall St. Rank hold AUPH as of Q4 2022.

  • Blueshift Asset Management reported no remaining Aurinia Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Blueshift Asset Management sold 11,162 Aurinia Pharmaceuticals shares in Q4 2022, an estimated $84K.
  • Blueshift Asset Management first reported a position in Aurinia Pharmaceuticals in Q3 2020 and held it in 3 quarters.
  • Blueshift Asset Management's Aurinia Pharmaceuticals position peaked at $321K in Q1 2022.
  • 192 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2022.

Based on Blueshift Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.